OneSource Specialty Pharma Q4 FY26 Results: PAT Rs 4.60 Crore Down 95.33 Percent YoY Revenue Rs 428.22 Crore FY26 Consolidated Loss Rs 73.80 Crore
- May 15, 2026
- Posted by: Kashish Aggarwal
- Category: News
OneSource Specialty Pharma Q4 FY26 results, announced on May 13, 2026, showed standalone PAT of Rs 4.60 crore, a sharp decline of 95.33% year-on-year from Rs 98.50 crore in Q4 FY25. Revenue from operations was Rs 428.22 crore, marginally up 0.53% YoY. The OneSource Specialty Pharma Q4 FY26 performance was impacted by a one-time FY26 consolidated loss of Rs 73.80 crore, even as standalone FY26 profit stood at Rs 20 crore.
Click Here – Get Free Investment Predictions
OneSource Specialty Pharma Q4 FY26 Key Financial Highlights
| Metric | Q4 FY26 | Q4 FY25 / YoY Change |
|---|---|---|
| Standalone PAT | Rs 4.60 crore | Rs 98.50 crore (Q4 FY25) | -95.33% YoY |
| Revenue from Operations | Rs 428.22 crore | Rs 426.00 crore (Q4 FY25) | +0.53% YoY |
| FY26 Consolidated PAT | Loss Rs 73.80 crore | FY26 Standalone PAT Rs 20 crore (profitable) |
| NSE Ticker | ONELIFECAP | Sector: Pharmaceuticals and Specialty Chemicals |
Screen the best stocks on the Univest Screener.
OneSource Specialty Pharma Q4 FY26 Performance Analysis
The OneSource Specialty Pharma Q4 FY26 results reflect a dramatic earnings contraction at the standalone level. The 95.33% YoY drop in PAT to Rs 4.60 crore from Rs 98.50 crore was driven by higher costs, margin compression, and exceptional charges at the consolidated level. Revenue held nearly flat at Rs 428.22 crore (+0.53% YoY), confirming that the topline was stable even as the bottom line deteriorated sharply.
The OneSource Specialty Pharma Q4 FY26 consolidated loss of Rs 73.80 crore for the full fiscal year contrasts with the standalone FY26 profit of Rs 20 crore, indicating subsidiaries or joint ventures dragged overall profitability. Investors tracking OneSource Specialty Pharma Q4 FY26 results will need to monitor management commentary on cost normalisation and the path to consolidated profitability in FY27.
OneSource Specialty Pharma FY27 Outlook
Post OneSource Specialty Pharma Q4 FY26, the key priorities for FY27 will be recovery in consolidated earnings, margin restoration, and resolution of subsidiary-level losses. The company operates in specialty pharmaceuticals and contract manufacturing, sectors benefiting from India’s growing pharma export opportunity. Investors should watch OneSource Specialty Pharma Q4 FY26 results alongside management guidance for FY27 revenue and EBITDA targets.
Download the Univest iOS App or the Univest Android App to track live price, analyst ratings, and Q4 FY26 earnings updates.
Frequently Asked Questions on OneSource Specialty Pharma Q4 FY26 Results
What is OneSource Specialty Pharma Q4 FY26 PAT?
Ans. OneSource Specialty Pharma Q4 FY26 standalone PAT was Rs 4.60 crore, down 95.33% YoY from Rs 98.50 crore in Q4 FY25. The sharp decline was due to higher costs and exceptional charges.
What is OneSource Specialty Pharma Q4 FY26 revenue?
Ans. OneSource Specialty Pharma Q4 FY26 revenue from operations was Rs 428.22 crore, up 0.53% YoY, indicating stable topline despite earnings pressure.
When did OneSource Specialty Pharma announce Q4 FY26 results?
Ans. OneSource Specialty Pharma Q4 FY26 results were announced on May 13, 2026, through the company’s board meeting and BSE/NSE exchange filings.
What is the FY26 consolidated performance of OneSource Specialty Pharma?
Ans. The FY26 consolidated result for OneSource Specialty Pharma was a net loss of Rs 73.80 crore, while the standalone FY26 profit was Rs 20 crore. Investors should track the OneSource Specialty Pharma Q4 FY26 earnings call for management guidance on FY27.
Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Consult a SEBI-registered advisor before making any investment decision.
